Fortrea Holdings Inc. (FTRE) vs Recursion Pharmaceuticals, Inc. (RXRX)
A side-by-side comparison of Fortrea Holdings Inc. and Recursion Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 2, 2026. Differences are shown without an overall score or investment verdict.
FTRE
Fortrea Holdings Inc.
$20.00HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
RXRX
Recursion Pharmaceuticals, Inc.
$4.12HealthcareDelayed quote: Oct 2, 2026, 4:00 PM EDT
Total return — FTRE vs RXRX
growth of $100 · dividends reinvested · last 3yFTRE -37.5% (-14.5%/yr)RXRX -54.1% (-22.9%/yr)FTRE compounded faster over this window
FTRE RXRX
FTRE vs RXRX: by the numbers
- •RXRX is the larger company ($2.16B vs $1.90B market cap).
- •Both run net losses; FTRE's is the smaller (-3.18% vs -945.92% net margin).
- •RXRX grew revenue faster over the past five years (45.50% vs 1.09% CAGR).
Metrics side by side
Valuation
| Metric | FTRE | RXRX |
|---|---|---|
| Forward P/E | 23.78 | N/A |
| P/S ratio | 0.71 | 39.41 |
| P/B ratio | 3.63 | 2.36 |
| EV / EBITDA | 31.92 | N/A |
| FCF yield | 7.92% | N/A |
Profitability
| Metric | FTRE | RXRX |
|---|---|---|
| Gross margin | 17.11% | -61.96% |
| Operating margin | 0.41% | -867.87% |
| Net margin | -3.18% | -945.92% |
| ROE | -16.25% | -56.71% |
| ROIC | 0.62% | -49.78% |
Growth (annualized)
| Metric | FTRE | RXRX |
|---|---|---|
| Revenue CAGR (5Y) | 1.09% | 45.50% |
| FCF CAGR (5Y) | -12.98% | N/A |
| Total return CAGR (5Y) | N/A | -28.37% |
Frequently asked
- Which has grown faster, FTRE or RXRX?
- Over the past five years, RXRX grew revenue faster — FTRE at a 1.09% CAGR versus RXRX at 45.50%.
Go deeper
Dig into the metrics
Fortrea ROERecursion Pharmaceuticals ROEFortrea operating marginRecursion Pharmaceuticals operating marginFortrea revenue growthRecursion Pharmaceuticals revenue growthFortrea free cash flowRecursion Pharmaceuticals free cash flow
Fortrea & Recursion Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 2, 2026.